Combination of targeted therapy and immunotherapy in melanoma - PubMed (original) (raw)

Review

Combination of targeted therapy and immunotherapy in melanoma

Christian U Blank et al. Cancer Immunol Immunother. 2011 Oct.

Abstract

The treatment of human melanoma has progressed markedly in recent years. Building on the observation that immune recognition is a frequent event in melanoma, a series of immunotherapeutic approaches have been evaluated in clinical trials, culminating in the first phase III study improving overall survival of melanoma patients since 20 years. However, the response rates seen upon immunotherapeutic interventions such as anti-CTLA4 treatment are often low. Furthermore, clinical responses can take several weeks to develop, during which time stage IV melanoma patients often deteriorate. Recent advances in our understanding of the genetic lesions in human melanoma now also allow the specific targeting of the signaling pathway alterations in this disease. Such targeted therapies can lead to high response rates, although the duration of these responses is thus far relatively short. We suggest that the combination of immuno and targeted therapy offers potential for synergy for both conceptual and practical reasons. In this review, we will discuss the potential and possible limitations for such combination therapy, and we describe the most promising combinations of targeted therapy and immunotherapy that can be tested in the clinic in the coming years. The concept of induction therapy by small molecule administration and consolidation by immunotherapeutics also has potential for the treatment of other human cancers.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Schematic overview of single agent, in pathway or cross pathway combinations of targeted and/or immunotherapy

Similar articles

Cited by

References

    1. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–534. doi: 10.1200/JCO.2007.12.7837. - DOI - PubMed
    1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150(2):179–185. doi: 10.1111/j.1365-2133.2004.05708.x. - DOI - PubMed
    1. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9(5):587–595. doi: 10.1586/era.09.25. - DOI - PubMed
    1. Eggermont AM. Immunotherapy: vaccine trials in melanoma—time for reflection. Nature Rev. 2009;6(5):256–258. - PubMed
    1. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40(12):1825–1836. doi: 10.1016/j.ejca.2004.04.030. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources